Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Antidepressant treatment failure is a common problem worldwide. In this study, we assess whether or not an important aspect of depression, cognitive impairment, is untreated by antidepressants by studying the effect of acute antidepressant treatment on a range of cognitive domains.Methods In this randomised longitudinal study, which is part of the International Study to Predict Optimized Treatment in Depression (iSPOT-D) trial, we assessed the effects of acute antidepressant treatment in a large patient population, across clinical remission outcomes, on a range of cognitive domains: attention, response inhibition, executive function during visuospatial navigation, cognitive flexibility, verbal memory, working memory, decision speed, information processing speed, and psychomotor response speed. We enrolled patients from primary or specialty care clinics in a multicentre, international, open-label, randomised, prospective trial. Eligible patients (aged 18-65 years) were previously untreated or were willing to undergo a 1-week medication washout before the study start, and could not have had inadequate response to study medications in the past. We enrolled a large population of medication-free (ie, untreated) outpatients in a depressive episode and assessed them for cognitive function at enrolment (pre-treatment), and again after 8 weeks of treatment with one of three antidepressant drugs (escitalopram, sertraline, or venlafaxine extended-release). Patients were randomly assigned (1:1:1) to one of the three antidepressants using a blocked randomisation procedure (block size of 12). As a comparison group, we also simultaneously enrolled matched healthy participants. Healthy participants received no medication or intervention, but were assessed for change in cognitive and clinical measures during the same interval and testing protocol. Therefore, this group acts as a test-retest control for the primary outcome measure examined in this study, change in cognitive measures over 8 weeks of treatment in depressed patients. This study is registered with ClinicalTrials.gov, number NCT00693849.Findings Between Dec 8, 2008, and Sept 30, 2011, we enrolled 1008 eligible people into the study. Impairment in five domains-attention, response inhibition, verbal memory, decision speed, and information processing-showed no relative improvement with acute treatment (controlling for time or repeated testing), irrespective of antidepressant treatment group, even in patients whose depression remitted acutely according to clinical measures. Broader cognitive impairment was associated with greater illness chronicity (earlier illness onset) but not with symptom severity or previous antidepressant failures.Interpretation Depression is associated with impairments in higher-order cognitive functions and information processing, which persist independently of clinical symptom change with treatment. We recorded no difference between the three antidepressants tested, with none showing efficacy for these impairments. Although the 8-week treatment period limits interpretation to acute treatment effects, it does highlight cognitive impairment as an untargeted contributor to incomplete treatment success.Funding Brain Resource Company Operations Pty Ltd and NIH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies have found improvements in selective attention with venlafaxine122 and with duloxetine125, but the results have been mixed99,100.”
From Paying attention to attention in depression (2019) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that MDD patients show clinical deficits in five cognitive domains: attention, response inhibition, verbal memory, decision speed, and information processing. Even if the depressive symptoms are significantly alleviated, the cognitive symptoms still lack corresponding improvement.6”
In the citing paper
“Unfortunately, selective serotonin reuptake inhibitors (SSRIs), currently the first-line class of pharmacologic treatment for depression, have generally not been shown to improve attention.”
From Paying attention to attention in depression (2019) · cites this paper as [99]
In the citing paper
“Many studies, albeit largely observational or with a mix of medications used, show no change in sustained attention25,99, selective attention100, or divided attention5,101, despite improvements in mood symptoms.”
From Paying attention to attention in depression (2019) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1998) · PubMed · Cited by 10,216
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
Snyder, H. R. (2013) · Psychological Bulletin · doi:10.1037/a0028727 · Cited by 1,667
Cognitive deficits in depression: Possible implications for functional neuropathology
Austin, M.-P., Mitchell, P., & Goodwin, G. M. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.200 · Cited by 1,154
Is the rostro-caudal axis of the frontal lobe hierarchical?
Badre, D., & D'Esposito, M. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2667 · Cited by 946
Depression and memory impairment: A meta-analysis of the association, its pattern, and specificity.
Burt, D. B., Zembar, M. J., & Niederehe, G. (1995) · Psychological Bulletin · doi:10.1037/0033-2909.117.2.285 · Cited by 903
A preliminary profile of neuropsychological deficits associated with major depression
Veiel, H. O. F. (1997) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688639708403745 · Cited by 502
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Cited by
Weigand, A., Horn, A., Caballero, R., Cooke, D., Stern, A. P., Taylor, S. F., Press, D., Pascual-Leone, A., & Fox, M. D. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.028 · Cited by 487
“Whether improvement in “cognitive” symptoms relates to any objective improvement in cognitive function remains unknown, because there is a known dissociation between the two (59).”
The Roles of Serotonin in Neuropsychiatric Disorders
Pourhamzeh, M., Moravej, F. G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R., Ahadi, R., & Joghataei, M. T. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01064-9 · Cited by 366
Transdiagnostic impairment of cognitive control in mental illness
McTeague, L. M., Goodkind, M. S., & Etkin, A. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.08.001 · Cited by 368
Self-citationPaying attention to attention in depression
Keller, A. S., Leikauf, J. E., Holt-Gosselin, B., Staveland, B. R., & Williams, L. M. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0616-1 · Cited by 329
Self-citationKoster, E. H. W., Hoorelbeke, K., Onraedt, T., Owens, M., & Derakshan, N. (2017) · Clinical Psychology Review · doi:10.1016/j.cpr.2017.02.002 · Cited by 273
Metadata
- Authors
- Shilyansky, C., Williams, L. M., Gyurak, A., Harris, A., Usherwood, T., & Etkin, A.
- Affiliations
- Stanford Medicine (US)
- VA Palo Alto Health Care System (US)
- The University of Sydney (AU)
- Corresponding author
- Etkin, Amit
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 3
- Issue
- 5
- Pages
- 425-435
- ISSN
- 2215-0366 (ISSN-L)
- PMC
- PMC4860142
- OpenAlex
- W2301371005
- Cited by
- 249
- References
- 32
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 23 · 2023: 20 · 2022: 30 · 2021: 23 · 2020: 23 · 2019: 23 · 2018: 22 · 2017: 18 · 2016: 14
- FWCI
- 20.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (T32MH019938)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- depression, cognitive impairment, antidepressant treatment, escitalopram, sertraline, venlafaxine extended release, attention, response inhibition, verbal memory, processing speed, decision-making speed, executive function, cognitive flexibility, working memory, treatment response, remission, illness chronicity
- MeSH terms
- Venlafaxine Hydrochloride, Adolescent, Adult, Aged, Antidepressive Agents, Depression, Female, Humans, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Citalopram, Treatment Outcome, Sertraline, Young Adult, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. https://app.cochat.ai/papers/10.1016/s2215-0366(16)00012-2
- The paper
- Shilyansky, C., Williams, L. M., Gyurak, A., Harris, A., Usherwood, T., & Etkin, A. (2016). Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(16)00012-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.